Education
About Us
Working with TipRanks
Follow Us
CSL (CMXHF)
OTHER OTC:CMXHF
CMXHF Stock Chart & Stats
$121.88
$5.38(3.14%)
At close: 4:00 PM EST
$121.88
$5.38(3.14%)
Day’s Range― - ―
52-Week Range$107.24 - $184.09
Previous CloseN/A
Volume29.00
Average Volume (3M)1.78K
Market Cap
$55.83B
Enterprise Value$133.92B
Total Cash (Recent Filing)$2.16B
Total Debt (Recent Filing)$11.65B
Price to Earnings (P/E)19.1
Beta0.31
Next Earnings
Feb 10, 2026EPS Estimate
4.08Next Dividend Ex-DateN/A
Dividend Yield2.48%
Share Statistics
EPS (TTM)2.35
Shares Outstanding485,151,400
10 Day Avg. Volume4,226
30 Day Avg. Volume1,785
Financial Highlights & Ratios
PEG Ratio1.90
Price to Book (P/B)3.94
Price to Sales (P/S)4.94
P/FCF Ratio29.97
Enterprise Value/Market Cap2.40
Enterprise Value/Revenue8.66
Enterprise Value/Gross Profit17.54
Enterprise Value/Ebitda25.59
Forecast
1Y Price Target
$158.95Price Target Upside30.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CSL News
CMXHF FAQ
What was CSL’s price range in the past 12 months?
CSL lowest stock price was $107.24 and its highest was $184.09 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is $55.83B.
When is CSL’s upcoming earnings report date?
CSL’s upcoming earnings report date is Feb 10, 2026 which is in 46 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Aug 18, 2025. The company reported $2.35 earnings per share for the quarter, missing the consensus estimate of $2.615 by -$0.265.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Undervalued.
Does CSL pay dividends?
CSL pays a Semiannually dividend of $1.613 which represents an annual dividend yield of 2.48%. See more information on CSL dividends here
What is CSL’s EPS estimate?
CSL’s EPS estimate is 4.08.
How many shares outstanding does CSL have?
CSL has 485,151,400 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of $2.35 in its last earnings report, missing expectations of $2.615. Following the earnings report the stock price went down -21.809%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in CMXHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$158.95 (30.42% Upside)
$158.95 (30.42% Upside)
Blogger Sentiment
Bullish
CMXHF Sentiment 88%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $99.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.80%
12-Months-Change
Fundamentals
Return on Equity
16.36%
Trailing 12-Months
Asset Growth
3.63%
Trailing 12-Months
Company Description
CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
CMXHF Company Deck
CMXHF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
CSL demonstrated strong financial growth and strategic initiatives, including successful product launches and plans to streamline operations and enhance R&D efficiency. However, challenges remain in the form of U.S. policy impacts, competitive pressures in the iron market, and a soft performance in the Seqirus segment.View all CMXHF earnings summariesCMXHF Stock 12 Month Forecast
Average Price Target
$158.95
▲(30.42% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Mesoblast Limited
―
Neuren Pharmaceuticals Limited
―
Immutep Ltd
―
Telix Pharmaceuticals
―
Ownership Overview
0.05% Insiders
4.80% Mutual Funds
<0.01% Other Institutional Investors
86.43% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---